ID   Mela17
AC   CVCL_VP48
SY   MELA17
DR   cancercelllines; CVCL_VP48
DR   Wikidata; Q95988717
RX   DOI=10.1158/1538-7445.AM2015-2417;
CC   Doubling time: 38 hours (Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000045115; Zygosity=Unspecified (Direct_author_submission).
CC   Miscellaneous: Cell line information from personal communication of Marlow, Laura A.
CC   Derived from site: Metastatic; Infraclavicular lymph node; UBERON=UBERON_0035162.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 9,12
ST   D16S539: 11
ST   D18S51: 12,14
ST   D3S1358: 15,16
ST   D5S818: 13
ST   D7S820: 9,11
ST   D8S1179: 13
ST   FGA: 20,25
ST   TH01: 8,9.3
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 10-04-25; Version: 12
//
RX   DOI=10.1158/1538-7445.AM2015-2417;
RA   Harris A.L., Marlow L.A., Mathias A.C., Dawson L.K., Durham W.F.,
RA   Meshaw K.A., Mullin R.J., Small D.L., Synnott A., Wu K., Milosevic D.,
RA   Netzel B.C., Grebe S.K.G., Markovic S.N., Copland J.A. 3rd;
RT   "Characterization of novel patient derived melanoma xenografts and
RT   cell lines in response to targeted therapies.";
RL   Cancer Res. 75 Suppl. 15:2417-2417(2015).
//